Previous Article | Next Article ![]()
Journal of Bacteriology, May 2003, p. 3081-3090, Vol. 185, No. 10
0021-9193/03/$08.00+0 DOI: 10.1128/JB.185.10.3081-3090.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322
Received 10 December 2002/ Accepted 7 March 2003
|
|
|---|
|
|
|---|
Many virulence factors of GAS strains appear to be involved in the survival, spread, and persistence of the organism inside the human host. These are (i) factors that damage or degrade the host tissues, such as cysteine protease, hyaluronidase, pyrogenic exotoxins, streptokinase, and streptolysins; (ii) factors that are required for resistance to phagocytosis by the host immune system, such as M protein, C5a peptidase, and hyaluronic acid capsule; and (iii) proteins that promote adherence and colonization, such as M protein and protein F (for reviews, see references 1, 8, 48, and 55). GAS encounters distinct microenvironments during infection and probably responds to them by expressing genes that produce proteins necessary for infection at that particular site. The ability to differentially regulate a wide range of virulence factors is therefore likely to be essential for the success of GAS infections.
Two-component signal transduction systems, consisting of sensor kinases and DNA-binding response regulators, allow bacteria to respond differently to diverse environmental stimuli (27, 46, 57). In the sequenced M1, M3, and M18 GAS genomes, 13 two-component systems have been identified (19) and several of them have been studied in various GAS strains (17, 22, 26, 31). Among them, CovRS (also called CsrRS) is a major regulator, repressing at least seven known or presumed virulence factors, including the hyaluronic acid capsule synthesis operon (hasABC), pyrogenic exotoxin B (speB), the streptolysin S-associated operon (sag), streptokinase (ska), mitogenic factor/streptodornase (speMF/sda), and inhibitor of innate immunity (mac) (2, 17, 25, 33, 34). In addition, CovR represses its own expression (17). A recent analysis by microarray and real-time PCR indicates that CovR controls as many as 15% of the GAS genes, either directly or indirectly (22). Because this is such a large number of genes and because some genes controlled by CovR are themselves known or suspected regulators, it seems likely that CovR is involved in a regulatory cascade.
Response regulators usually act by binding to DNA in the vicinity of promoter sequences. This is true for CovR as well, since recent in vitro studies have shown that CovR binds near several covR-regulated promoters (18, 41). For example, CovR binds to the promoter region of hasA, sagA, ska, speB, and speMF (18, 41). In vitro binding studies with the Phas region identified five CovR binding sites, all of which are required for complete CovR-mediated repression in vivo (18). Thus, CovR appears to regulate the expression of some genes through direct interactions with their promoter regions.
Although we have begun to understand how CovR regulates the expression of different virulence genes, regulation of covRS expression is not well understood. It is known that CovR negatively regulates its own transcription (17) and that Rgg, a transcriptional regulator, activates covRS transcription (7). In addition, covR expression is also regulated by growth conditions. For example, covRS transcription reaches its maximum during the exponential growth phase and declines as the stationary phase begins (17, 41). Nutritional conditions, such as amino acid starvation, also affect covRS transcription by some unknown mechanism (54). Therefore, it appears that expression of the covRS operon may be controlled by a complex regulatory network.
The goal of this investigation was to isolate a regulatory factor(s) that modulates the expression of the covRS operon. In the present work, we report the identification and characterization of a gene that activates covRS expression. Because it activates covR, we named this gene rocA (for "regulator of CovR"). Inactivation of rocA in GAS results in decreased covR expression and derepression of has transcription.
|
|
|---|
Construction of the pVIT GAS strain used to measure Pcov expression. The VIT system was used to deliver the Pcov-gusA reporter fusion in single copy to an ectopic chromosomal location to study Pcov expression (6). The pVIT plasmid contains regions of homology to the resident Tn916-J4 transposon on the RTG229 chromosome. A DNA fragment containing the Pcov-gusA reporter was cloned into the homologous region of pVIT for integration into the chromosome.
The covR promoter region used for translational fusions was amplified from the JRS4 chromosome by using primers R1-CovOrf1 (gaattcTGGTATTAGTTTTAGACAAAGACGC) and Cov-GusAS (tctagaTGTCATTTATACCAACCCTTATCCTCTTA). The restriction site at the 5' end of each primer is indicated by lowercase letters, the sequence homologous with the chromosome is indicated by uppercase letters, and the first two codons of the covR open reading frame (ORF) are in boldface. The 504-bp amplified fragment, which contains the covR promoter, untranslated sequence, and two codons, was blunt end ligated into SmaI-digested pBluescript II KS (Stratagene) to generate pEU7415. To clone the gusA reporter gene in frame with covR, we used the XbaI site that was inserted into the primer.
The gusA gene (1.8 kb) was amplified from plasmid pNZ8008 (9) by using primers GusL (gctctagaATGTTACGTCCTGTAGAA) and GusR (gctctagaTCATTGTTTGCCTCCCTG) and was restricted with XbaI (site synthesized into the primer; underlined). The XbaI fragment containing the gusA gene was ligated to XbaI-restricted pEU7415 to create pEU7416. The orientation of gusA and the in-frame fusion of the Pcov-gusA gene were verified by sequencing.
To insert the Pcov-gusA reporter fusion at the pVIT locus, plasmid pVIT164 (20) was used. A PstI-SacI fragment from pEU7416 carrying Pcov-gusA was cloned into PstI-SacI-digested pVIT164 to generate pJRS2227. Plasmid pJRS2227 was linearized with PvuII and transformed into RTG229 to produce JRS2227 as described previously (6). JRS2227 is kanamycin resistant and erythromycin sensitive, and the presence of both junctions of the Pcov-gusA fusion at the pVIT locus was verified by PCR.
Isolation of rocA mutants. The procedure described by Maguin et al. (39) was used to generate insertion mutants of GAS. Briefly, JRS2227 was transformed with pGhost9::ISS1 and transformants were selected on THY agar containing kanamycin and erythromycin at 30°C. An overnight culture was made from a single transformed colony at 30°C with erythromycin. Cultures were diluted 100-fold in the same medium, grown for 2 h at 30°C, and then shifted to 37°C for 2.5 h to select for transposition. Insertion mutants were selected on THY agar containing kanamycin and erythromycin at 37°C.
The location of the inserted ISS1 element was identified by one of two methods. A template generated by self-ligation of HindIII-digested chromosomal DNA was subjected to inverse PCR by using primers GATTGTAACGTAGATAATAACCAACAGC (ISS1Rout1) and GCAAGAACCGAAGAAATGGAACG (ISS1Fout1). The PCR product was sequenced with primer AATAGTTCATTGATATATCCTCGCTGTCA (ISS1-Rout2) to identify the flanking sequences. Alternatively, the self-ligated product was used to transform E. coli TG1 and erythromycin-resistant transformants were selected. Plasmid DNA containing flanking sequence was isolated and sequenced with primer GGTCTTAATGGGAATATTAGC (ISS1-For4) as previously described (13). The flanking sequences were identified by comparison to the M1 and M5 genome sequences.
Colonies in which the plasmid vector sequence had been excised from the chromosome were obtained by growth at 30°C without antibiotic selection, which permits plasmid replication (39). Erythromycin-sensitive (Ems) colonies, indicating that the plasmid had been excised, were selected by plating on solid medium at 37°C. Ems colonies were confirmed for loss of the plasmid sequence by PCR with primers homologous to the flanking regions.
Insertional inactivation of rocA. To create plasmids for inactivation of the rocA gene, a fragment internal to the coding region was amplified from JRS4 with high-fidelity Herculase polymerase (Stratagene) with primers AGCATTCAAGATACCTTCATAAGTAAGTCT and TCCACTAGTGTCTATTAGTTTGGTTAAGCG. The amplified fragments were blunt end ligated to SmaI-restricted pUC-Spec (28), a suicide vector unable to replicate in GAS, to create pEU7457 (Fig. 2). The amplified internal rocA fragment was also blunt end ligated to SmaI-restricted pSK-Erm (a pBluescript SK derivative in which the ampicillin resistance gene has been replaced with the erythromycin resistance gene from Tn1545; I. Stojiljkovic, unpublished data) to generate pEU7460 (Fig. 2). Plasmid pEU7457 was introduced into JRS2227 by electroporation, and transformants were selected on THY agar with spectinomycin. A spectinomycin-resistant transformant resulting from homologous single-crossover integration of pEU7457 into the GAS chromosome and inactivation of the rocA gene was named JRS2268. The plasmid-chromosome junctions of JRS2268 were verified with the following primer pairs: 5' junction, ccgaattcCTGATTTAATCTTTTAAGCTGT (RocAS1; see Fig. 2, arrowhead 1) and ggaaacagctatgaccatg (M13Rev; see Fig. 2, arrowhead 2); 3' junction, ccgaattcATTAGTAATAGATTAACATATT (RocAA1; see Fig. 2, arrowhead 4) and tgtaaaacgacggccagtg (M13For; see Fig. 2, arrowhead 3). The rocA gene was also inactivated in strains JRS4, JRS948 (17), JRS 964, JRS965, and JRS966 (11, 18) by transformation with pEU7460 and selection for erythromycin-resistant transformants. This generated JRS2278, JRS2279, JRS2351, JRS2285, and JRS2286, respectively. These strains, in which rocA was inactivated, were verified by PCR across the plasmid-chromosome junctions by using primer pairs RocAS1 and M13For for the 5' junction and RocAA1 and M13Rev for the 3' junction.
![]() View larger version (25K): [in a new window] |
FIG. 2. Construction of a rocA null mutant. (A) Region surrounding rocA in the chromosome of GAS. Plasmid pEU7457 (circle), which was used for insertional inactivation, contains a region internal to the rocA ORF (thick hatched box) and contains aad9, which encodes spectinomycin resistance (thick black arrow). The direction of transcription of the ORFs flanking rocA is indicated by striped arrowheads. The region of rocA that was cloned in complementing plasmid pJRS2266 is indicated by a bar below the chromosome. (B) JRS2268 was produced by homologous recombination (indicated by the X above the representation of the chromosome in panel A), which inserted pEU7457 into the wild-type rocA gene in the JRS2227 chromosome. (C) JRS2278 was produced by a similar targeted insertion in JRS4 by using integrational plasmid pEU7460, which contains erm, encoding erythromycin resistance (gray box), and a region internal to the rocA ORF (thick hatched box) as shown. Symbols: dotted lines, chromosome; striped boxes, coding regions with the directions of transcription indicated by the arrowheads; bent arrow, putative promoter; triangles, ISS1 insertion sites; lollipop, putative rho-independent transcription terminator. Small arrowheads below the chromosome represent primers used to confirm plasmid insertion into the chromosome (see Materials and Methods). The figure is not drawn to scale.
|
Deletion of the covR gene. Plasmid pEU7529 was used to delete covR from the GAS strains (A. Gusa and J. R. Scott, unpublished). This plasmid was constructed from pJRS943 (17), which contains, in addition to the covR ORF, the upstream and downstream regions. Plasmid pJRS943 was restricted with BsgI and XcmI to delete covR and blunt ended (17). A spectinomycin resistance-encoding cassette was isolated by SmaI restriction from pSL60-I (37) and ligated to BsgI-XcmI-restricted and blunted pJRS943 to create pEU7521. The ampicillin resistance gene from pEU7521 was removed by PvuI digestion, followed by self-ligation, to generate pEU7529. Plasmid pEU7529 was linearized by SacI and transformed into JRS2227 and JRS2281. Spectinomycin-resistant transformants containing the covR deletion were selected and were confirmed for the replacement of the covR gene by PCR as previously described (17).
RNA blot analysis. GAS strains were cultured in THY, and growth was monitored by using a Klett-Summerson colorimeter with a red filter. Total RNA was isolated from different phases of growth as described previously (4), except that glycine was omitted from the medium. RNA was pelleted by sedimentation through 5.7 M CsCl (40) or by FastPrep (Bio 101) (4) as described previously. DNase I-treated RNA was assayed on Zeta-Probe membranes (Bio-Rad) as previously described (4). DNA probes were prepared by PCR amplification with the JRS4 chromosomal DNA as the template. The primer pairs used in this study are the following: covR, CAGCTATTCTTTGATATACTCTTTAGAG (5Cov) and Cov-GusAS; gyrA, GATCTGCAGGAATACGACTCATTTCTCTTTATCCC and GTCATCCTGACCGCTTGTCAAAAGG; hasA, GAGAGAGAATTCACCTAGGAGTGTTTGATTTT (intHasA1) and GAGGAGGAATTCAGATGCCGAGTCATTA (intHasS1); sagA, GGAGGTAAACCTTATGTTAA (SagAL) and AGATTATTTACCTGGCGTAT (SagAR).
GusA assays. For plate assays, 10-µl volumes of overnight GAS cultures were spotted onto THY agar plates containing 200 µg of X-Glu (Gold Biotechnology Inc.) per ml. GAS strains that produced low GusA activity were white, while strains that produced high GusA activity were blue. Specific activity of GusA was assayed from GAS cultures grown to late exponential phase as previously described (14). For some experiments, GAS cultures were grown in THY broth buffered with 100 mM Tris-HCl at pH 7.2. The rate of hydrolysis was standardized by comparison to known concentrations of glucuronidase (Sigma catalog no. 500-0006). One unit of GusA activity was defined as that which liberates 1 µg of phenolphthalein (from phenolphthalein glucuronide)/h/mg of protein of GAS lysate at 37°C, pH 6.8. The protein concentration was determined by the Bio-Rad protein assay standardized against bovine serum albumin.
|
|
|---|
![]() View larger version (13K): [in a new window] |
FIG. 1. Construction of Pcov-gusA reporter strain. The promoter region of covR, along with the sequence encoding the first two amino acids of CovR (amplified by primers 1 and 2 [arrowheads]), was fused to the gusA reporter gene isolated from plasmid pNZ8008. The Pcov-gusA reporter construct was inserted into the GAS chromosome at the VIT locus, which is not linked to the native covRS locus. Native covRS and the region of covR that is present at the VIT locus are shown. Symbols: bent arrow, covR promoter; white box, ribosome binding site of CovR; checkered box in front of gusA, first two amino acids of CovR; broken black arrow, part of the upstream ORF present in the Pcov-gusA fusion. Arrowheads indicate primers used for PCR analysis. The orientation of Pcov-gusA relative to the native covRS locus is unknown.
|
Among the operons that are negatively regulated by CovR is the has operon, required for production of the hyaluronic acid capsule (17). We reasoned that inactivation of an activator of Pcov would cause increased transcription of Phas because there would be less CovR expression. This would result in a mucoid colony phenotype in the JRS4-derived GAS strain JRS2227, which produces very little capsule. Therefore, we screened the JRS2227 colonies containing inserted ISS1 for a mucoid phenotype. Mucoid colonies were then tested by a plate assay by using X-Glu to monitor expression of GusA from the Pcov-gusA reporter fusion in the strain. A defect in expression of Pcov results in production of white colonies. Among the mucoid colonies, approximately 30% were white.
To eliminate any possible insertion in the covRS operon, the size of the covRS region was verified by PCR amplification with primers 1 plus 2, 3 plus 4, and 5 plus 6 (Fig. 1), which include the region upstream of the covRS operon, as well as the entire covRS operon. The clones that showed wild-type-size fragments, suggesting an intact covRS region, were chosen for further analysis.
The site of the ISS1 insertion was identified as described in Materials and Methods for 31 of the mucoid white colonies. In all 31 cases, Southern hybridization analysis showed that ISS1 insertion had occurred at only one location. Among these mutants, more than one independent insertion had occurred in eight different genes. Four of these genes (SPy1032 [hylA], SPy481, SPy1505, and a conserved ORF [SPyM18_0587] absent from the M1 and M3 genomes but present in the M5 and M18 genomes) had multiple insertions in the same location and thus could be sisters. Multiple independent insertions at different locations were found in each of the four remaining genes, SPy 1981 (relA), SPy1605, SPy159, and SPy0534 (aroE). Although none of the genes into which ISS1 had inserted itself showed homology to any known transcriptional regulator, SPy1605 showed some homology to sensor kinases (see below), which are involved in gene regulation. Therefore, we focused our studies on SPy1605, which we call rocA (for "regulation of covR"; see below). The rocA gene encodes a polypeptide of 451 residues. Two independent ISS1 insertions had occurred in this gene and were located within codons 25 and 91, respectively. The rocA gene is preceded by a putative promoter region upstream of the translational start codon and followed by a potential rho-independent terminator just downstream of the stop codon (Fig. 2A). The gene downstream of rocA is transcribed in the opposite direction, which makes it unlikely that the ISS1 insertions would have polar effects.
RocA regulates the expression of covR. To be sure that the phenotype of the rocA insertion mutation did not result from additional spontaneous mutations elsewhere in the genome, we inactivated the rocA gene in the nonmutagenized Pcov-gusA reporter strain JRS2227. A PCR-amplified fragment internal to the coding region of rocA was cloned into the suicide vector pUC-Spec (28) to produce pEU7457. Following introduction of this plasmid into JRS2227, recombinants in which pEU7457 had been integrated into rocA were selected as Specr colonies. This integration results in inactivation of the rocA gene (Fig. 2B). In these integrants, the junctions between the integrated plasmid and the chromosome were identified by PCR analysis (by using primers 1 plus 2 and 3 plus 4 [Fig. 2B]). In addition PCR with primers 1 plus 4 failed to amplify a full-length copy of rocA.
Transcription of Pcov was quantitated in these strains by measuring the activity of GusA produced from the Pcov-gusA reporter fusion (Fig. 3A). For this assay, cells were grown in THY broth and harvested late in the exponential phase (Fig. 3B). We found that the rocA mutant strain (JRS2268) showed threefold less Pcov-gusA expression than its rocA+ parent (JRS2227, Fig. 3C). To be sure that this effect was caused by the rocA mutation, we used complementation. We cloned a DNA fragment including rocA with its potential promoter region into pLZ12, which replicates in GAS, to generate pJRS2266 (Fig. 2A). As a control, we used JRS2268 (rocA) containing the vector pLZ12. This control strain had the same GusA activity as strain JRS2268, while the complemented strain, JRS2268/pJRS2266, expressed about twofold more GusA than the parental rocA+ strain, JRS2227. Thus, when RocA was overexpressed from the multicopy plasmid, Pcov expression was not only restored but was increased above the wild-type level (Fig. 3C). Therefore, it appears that RocA activates expression from the Pcov promoter.
![]() View larger version (23K): [in a new window] |
FIG. 3. Expression of the covR gene in the wild-type and rocA mutant strains. (A) A gusA reporter system was used to measure the expression from the covR promoter at the VIT locus (symbols are as in Fig. 1). (B) Arrows indicate the times at which the samples were assayed for GusA activity. (C) The values shown are units of glucuronidase activity (with standard errors of the mean of experiments repeated at least four times). The relative ratio of GusA activity with respect to that of the wild type (WT) is shown.
|
|
View this table: [in a new window] |
TABLE 1. Regulation of covR expression by RocA is independent of functional CovR
|
RNA was isolated from strains JRS4, JRS2278, and JRS2278/pJRS2266 in the mid- and late exponential growth phases (M and L, respectively, in Fig. 4A) and assayed by hybridization to a PCR-derived hasA probe. To ensure that equal amounts of mRNA from each strain were loaded on the filter, all samples were hybridized with a gyrA probe (Fig. 4B). We found that JRS2278 (rocA) had two- to threefold more hasA transcript than JRS4 at both stages of growth. This is as expected if RocA activates Pcov to produce more CovR repressor. The complemented strain, JRS2278/pJRS2266, produced two- to threefold less hasA transcript than the JRS4 wild-type strain. This suggests, as above (Fig. 3), that rocA is overexpressed from pJRS2266, which results in overproduction of CovR for repression of Phas.
![]() View larger version (45K): [in a new window] |
FIG. 4. Analysis of hasA gene transcription in the wild-type and rocA mutant strains. (A) Total RNA was isolated from JRS4 (wild type), JRS2278 (rocA), and JRS2278/pJRS2266 (rocA/rocA+) at the mid-exponential growth phase (M) and the late exponential growth phase (L). (B) On each filter, two dilutions (4.0 and 1.0 µg) of RNA were applied in vertically arranged duplicates. Membranes were probed with PCR-derived specific DNA probes internal to the coding region of gyrA and hasA (Materials and Methods). Results reported are representative of hybridization from three independent RNA isolations.
|
Federle and Scott (18) identified the binding sites at the Phas promoter for CovR and constructed mutants with two base substitutions at conserved T-T pairs at each of these sites. In two of these Phas mutants, Phas is still transcribed but is insensitive to repression by CovR. We reasoned that if RocA acts on Phas indirectly through CovR, a rocA mutation should not affect transcription of the Phas mutants that are not CovR regulated. In the Phas-gusA fusion with no mutations in the promoter region, the rocA strain produces approximately fourfold more GusA activity than the wild type (Fig. 5A). In contrast, in the Phas-gusA strain mutated at CovR binding site 1 (CB-1), there was no increase in GusA expression in the rocA mutant compared to that in the rocA+ strain. Instead, we observed lower GusA activity in the rocA mutant and the reason for this decrease is unknown. However, in the other Phas-gusA strain, in which CB-5 is altered, mutation of the rocA gene did not change GusA specific activity (Fig. 5A). This implies that RocA probably acts on the Phas promoter indirectly through CovR.
![]() View larger version (44K): [in a new window] |
FIG. 5. Regulation of the has promoter by rocA requires functional CovR. (A). Stars indicate mutations in the has promoter region that make it insensitive to CovR repression. The name of the mutant is on the left, and the location of the mutation is in parentheses. The values shown are glucuronidase units with standard errors of the mean of at least four independent experiments. WT, wild type. (B) Transcription analysis of hasA by RNA hybridization. RNA was isolated at the mid-exponential phase from JRS948 (covR), JRS2279 (covR rocA), and JRS2279/pJRS2266 (covR rocA/rocA+). Blots were prepared and hybridized as described in the legend to Fig. 4. Results are representative of hybridization from two independent RNA isolations.
|
RocA negatively regulates its own expression. Since it is not uncommon for transcriptional regulators to control their own synthesis, we used RNA hybridization analysis to test this for rocA. As before, we harvested RNA at the mid- and late exponential phases (Fig. 4A) and normalized to gyrA for a loading control on slot blots. At both stages of growth, there was two- to fourfold more rocA transcript in JRS2278 (rocA) than in JRS4 (rocA+) (Fig. 6). This suggests that RocA, which activates covR, negatively regulates its own expression (either directly or indirectly). Although rocA transcript appears more plentiful in the mid-exponential phase than in the late exponential phase, autoregulation persists in the later stage of growth.
![]() View larger version (59K): [in a new window] |
FIG. 6. RocA regulates its own expression. RNA was extracted from the JRS4 (wild-type) and JRS2278 (rocA) strains at the mid-exponential (ME) and late exponential (LE) phases as indicated in Fig. 4. Membranes were hybridized with gyrA and rocA probes. Blots were prepared and hybridized as described in Materials and Methods. The results shown are representative of hybridization from two independent RNA isolations.
|
![]() View larger version (39K): [in a new window] |
FIG. 7. Regulation of rocA expression by RocA is independent of functional CovR. RNA was extracted from the JRS4 (wild-type) and JRS948 (covR) strains at the late exponential (LE) and early stationary (ES) phases (arrows in panel A). Membranes were hybridized with rpsL, rocA, and sagA probes as described in Materials and Methods (B). The results shown are representative of hybridization from two independent RNA isolations.
|
To investigate the distribution of rocA among the different streptococci, we used two approaches. First, a BLAST search with the rocA nucleotide sequence against the available GAS genome sequences showed that this gene is present in the sequenced M1, M3, M5, and M18 strains. A similar search found no significant homology to genes in any sequenced strains of other streptococcal species.
To expand these observations, we used Southern hybridization to investigate the presence of a rocA homolog in strains representing nine of the multilocus enzyme electrophoresis types of GAS (42). For this analysis, a 1.78-kb fragment including the complete rocA gene was used as a probe and the hybridization was carried out under stringent conditions (Fig. 8). This probe hybridized with two HindIII fragments that differ in size and two HindIII fragments of constant size in all 13 GAS strains tested. The HindIII fragments of variable size indicate that regions flanking rocA vary among the GAS strains and correspond to the predicted sizes for M1, M3, M5, and M18 strains. The two constant HindIII fragments were
0.92 and
0.23 kb long. The 0.92-kb fragment is internal to rocA, and the 0.23-kb fragment includes 0.14 kb of upstream DNA. These results demonstrate that rocA is present in most or all strains of GAS.
![]() View larger version (78K): [in a new window] |
FIG. 8. Detection of the rocA gene by Southern hybridization. Genomic DNA from the strains was restricted with HindIII and separated in a 0.7% agarose gel by electrophoresis, and the presence of the rocA gene was detected by hybridization with a 1.78-kb fragment of the rocA region as shown at the bottom. M serotypes and strain numbers are indicated at the top. GBS, group B streptococcus; NT, nontypeable. Arrows indicate the constant fragments hybridized with the probe in all GAS strains. The values on the left are molecular sizes in kilobases.
|
|
|
|---|
RocA appears to activate CovR expression, which acts as a repressor on several promoters. We found that the rocA mutant strain is mucoid and shows more has transcription than the wild type (Fig. 4). This is expected, since in the rocA mutant, less CovR is produced, and as a result, has transcription is derepressed. In view of the fact that has expression was increased in the rocA mutant, we measured the transcription of genes, such as sagA, ska, and speMF/sda, that are normally repressed by CovR (17). We did not find any significant differences in transcription between the wild-type and rocA mutant strains (data not shown). It is possible that the effect of the rocA mutation on these genes was very small and that the RNA slot blot assay that we used to measure transcript levels is not sensitive enough to detect subtle changes. Alternatively, the rocA mutation may not affect the transcription of the sagA, ska, and speMF genes. It is possible that the amount of CovR present in the rocA mutant is sufficient for complete repression of the sagA, ska, and speMF promoters but that more CovR is required for complete repression of the has promoter. However, it is also possible that the active form of CovR that regulates the sagA, ska, and speMF genes is different from the one that represses the has promoter and that the latter form is affected by the rocA mutation whereas the former form is not.
The rocA gene encodes a polypeptide of 451 amino acid residues. A BLSLTP (version 2.2.3) search of the nonredundant GenBank database showed limited homology to various sensor kinase homologs, with probability values ranging up to e-37. The homology was restricted to the C-terminal region of RocA, and the homology did not increase significantly when only the C-terminal 220 amino acids were used for a BLASTP search. Proteins that showed homologies to RocA of greater than e-10 include BlpH and ComD of S. pneumoniae (10, 24), AgrC of S. aureus (36), RgfC of S. agalactiae (52), and FasB and FasC of GAS (31), among others. Most of these sensor kinases are activated by a small peptide and are involved in quorum sensing (32).
Members of the sensor kinase superfamily exhibit clusters of highly conserved residues that are presumed to play crucial roles in signal transduction. These characteristic sequence fingerprints have been termed the H, N, F, and G boxes (56, 57). The H box contains the conserved histidine residue that is involved in autophosphorylation. The other boxes are considered to be part of the kinase subdomain and are required for kinase activity (56, 57). In the RocA sequence, we did not find a conserved H residue in the region corresponding to the H box (Fig. 9). In fact, apart from the N box, no other conserved boxes were apparent (Fig. 9). This surprising deviation from the canonical homology boxes has been reported previously for some other sensor kinases (for a review, see reference 23). For example, sensor kinases in which the conserved histidine is replaced with arginine, aspartate, or tyrosine (23, 61) and sensor kinases in which various conserved boxes are absent (12, 30, 56) have been documented previously. Thus, if RocA encodes a sensor kinase, it belongs to an unorthodox family with variant phosphorylation and kinase domains.
![]() View larger version (88K): [in a new window] |
FIG. 9. Comparison of RocA with homologous proteins identified by a Blast-P search. The C-terminal regions of the different sensor kinases were aligned by using ClustalW. The GenBank accession numbers of the sequences are as follows: RocA, AAK34382; ComD, CAB39530; RgfC, AAM22582; BlpH, AAK74685; AgrC, AAB63269. Putative conserved boxes are indicated below the alignment.
|
Analysis of the RocA sequence showed no obvious DNA binding motifs, such as zinc finger or helix-turn-helix motifs. In addition, a computer-based profile scan against the Pfam (http://us.expasy.org) protein families and conserved domain database (http://ncbi.nlm.nih.gov) did not show any domain related to DNA binding proteins. This strongly suggests that RocA is not a transcriptional regulator that binds directly to the promoter regions to modulate expression. Therefore, the regulation of Pcov and ProcA promoters by RocA is likely to be indirect.
If RocA encodes a sensor kinase, it should have a cognate response regulator. In bacteria, the genes for cognate pairs of sensor kinases and response regulators are typically found together in a single operon. However, in the region containing rocA, there are no ORFs with homology to a response regulator. Although the presence of cognate response regulators at a different locus than sensor kinases is not common, it has been observed. For example, the genes for response regulators for barA of E. coli (43), expS of Erwinia carotovora (16), and gacS of Pseudomonas syringae (45) are all present far from those encoding the corresponding sensor kinases. Thus, if RocA is a sensor kinase, its cognate response regulator may be present elsewhere in the genome.
Since we observed both activation of Pcov and repression of ProcA promoters by RocA (Fig. 3 and 6), RocA may act as a sensor kinase to stimulate either two different regulators with opposite functions or a single response regulator with different activities. There are several situations in which a single sensor kinase activates two different response regulators. For example, in E. coli, sensor kinase CheA interacts with CheB and CheY to regulate chemotaxis (35). On the other hand, response regulators with two opposite functions have also been documented. For example, in the E. coli osmosensing system, response regulator OmpR functions both as an activator and as a repressor to differentially regulate the expression of the ompC and ompF genes (29, 44). Thus, whether RocA stimulates a single regulator with different activities or two different regulators remains to be explored.
RocA is present only in GAS, whereas the covRS system appears to be present in other streptococci as well, since covRS homologs have been found in group B streptococcus (21, 58), group C streptococcus (53), and S. mutans (GenBank accession no. AF393849). The streptococci that possess covRS but not rocA may modulate covR expression through a functional homolog with little or no primary sequence homology to rocA. Another possibility is that the activation of covR expression by RocA is unique to GAS. Perhaps, since strains of GAS are able to cause a very wide range of diseases, these bacteria require an additional level of covR regulation not required by other streptococci that have a more limited disease spectrum. The role of CovR in virulence gene regulation and the mechanism of regulation of covR expression have not been studied in other streptococci.
In conclusion, we have identified and characterized rocA, a novel regulatory gene involved in the activation of covR expression in GAS. Since CovR is a global regulator that controls 15% of the GAS genes, RocA may be involved in the regulation of a large network of genes. Moreover, RocA also regulates genes independently of CovR. Therefore, detailed characterization of RocA-mediated gene regulation may lead to a greater understanding of the events that occur during pathogenesis of GAS.
We thank Emmanuelle Maguin for providing the transposon pGhost9::ISS1, Tony Richardson and Igor Stojiljkovic for providing the plasmid pSK-Erm, Asiya Gusa for constructing the plasmid pEU7529, and Tracy Dalton for providing JRS948 RNA.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»